The FAMHP and pharma.be are organising two half-day symposia on vaccines on 10 and 12 May 2022. The first day will focus on the FAMHP and the VACCINES spearhead. This will cover topics such as clinical trials, regulatory activities, pharmacovigilance, and inspections. The second day will focus on effective vaccination, before closely examining the way vaccination campaigns are organised and implemented, vaccine hesitancy, and data collection. You can register now.
The COVID-19 pandemic has highlighted the importance of immunisation in combating infectious diseases. The national competent authorities and the pharmaceutical industry have worked intensively to provide the population with safe and effective vaccines against the coronavirus.
On 10 and 12 May 2022, the FAMHP and pharma.be are organising a symposium on the various activities being undertaken to not only make vaccines available, but also to encourage their acceptance with a view to protecting public health, our healthcare system and society as a whole.
• Attendance at both half-day sessions is free of charge but registration is required. You must register for each half-day session you wish to attend using the online forms: 10 May and 12 May.
• Presentations will be given in English.
• Each symposium will start at 9.00 and end at around 13.10.
• The symposium will be held at the Pacheco Center, Boulevard Pacheco 13, BRUSSELS.
10 May: From concept to vaccines (organised by the FAMHP)
Focus on the activities of the FAMHP and the VACCINES spearhead, covering topics such as clinical trials, regulatory activities, pharmacovigilance, and inspections.
12 May: From vaccines to vaccination (organised by pharma.be)
Focus on effective vaccination by examining how regional authorities organise and implement their vaccination campaigns, tackle vaccine hesitancy, and collect data on vaccine uptake.
Based on all these experiences, the symposium will also offer an opportunity to consider future developments. How can we use the expertise of the VACCINES spearhead to strengthen Belgium’s position in the development of new vaccines? Can regulatory pathways be altered to optimise the evaluation process? What data do we need to support authorities in their decision-making? In short, what changes are needed to make the lifelong vaccination of Belgian patients as effective as possible?